Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

BACKGROUND: The mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumours (PNETs). However, adaptive resistance to mTOR inhibition is described. METHODS: QGP-1 and BON-1, two human PNET cell lines, were cultured with increasing concentrations of evero...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Vandamme, Timon, Beyens, Matthias, de Beeck, Ken Op, Dogan, Fadime, van Koetsveld, Peter M, Pauwels, Patrick, Mortier, Geert, Vangestel, Christel, de Herder, Wouter, Van Camp, Guy, Peeters, Marc, Hofland, Leo J
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800296/
https://ncbi.nlm.nih.gov/pubmed/26978006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.25
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars